secwatch.observer — SEC 8-K summary
======================================

Issuer:     OCULAR THERAPEUTIX, INC (OCUL)
CIK:        0001393434
Form:       8-K
Filed at:   2024-04-18T23:59:59+00:00
Accession:  0001104659-24-048850
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocular Therapeutix appoints Pravin Dugel as CEO, Nadia Waheed as CMO; stock plan increased
--------------------------------------------------------------------------------

- Pravin U. Dugel appointed President and CEO, effective April 14, 2024; he remains Executive Chairman.
- Prior CEO Antony C. Mattessich resigned; severance includes 24 months base salary and 24-month equity acceleration.
- Nadia Waheed appointed Chief Medical Officer effective May 20, 2024, replacing Rabia Gurses Ozden.
- 2019 Inducement Stock Incentive Plan amended to increase shares from 3,804,000 to 4,804,000.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1393434/000110465924048850/0001104659-24-048850-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1393434/000110465924048850/tm2412141d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-048850

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer